Sign Up
OverviewAPI
The potential impact of a TRIPS waiver on intellectual property rights for COVID-19 therapeutics and diagnostics is discussed, emphasizing the need to maintain IP protections for medical research and development. The article calls for the U.S. government to advocate against the waiver, citing potential economic and job losses in the biopharmaceutical industry, particularly in California.

Ask a question